Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Passaro, Antonio, Lazzari, Chiara, Karachaliou, Niki, Spitaleri, Gianluca, Pochesci, Alessia, Catania, Chiara, Rosell, Rafael, de Marinis, Filippo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2016
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074703/
https://ncbi.nlm.nih.gov/pubmed/27799783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98347
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak